China Oncology ›› 2022, Vol. 32 ›› Issue (10): 960-970.doi: 10.19401/j.cnki.1007-3639.2022.10.004
• Specialists' Commentary • Previous Articles Next Articles
LUO Guopei1,2,3,4(), YU Xianjun1,2,3,4()
Received:
2022-06-29
Revised:
2022-10-18
Online:
2022-10-30
Published:
2022-11-29
CLC Number:
LUO Guopei, YU Xianjun. Precision therapy in pancreatic cancer: from streamlet towards mainstream[J]. China Oncology, 2022, 32(10): 960-970.
Tab. 1
Summary of common therapeutic targets for pancreatic cancer"
Pathway or molecule | Related genes or indicators | Frequency |
---|---|---|
KRAS | KRAS wild type, KRAS G12C mutation | 10% |
Homologous recombination repair | BRCA1/2, PALB2, ATM/ATR/ATRX, CHEK2, CDK12, RAD51, NBN, BLM, FANC, RAD51/51C,RAD50,BAP1,BARD1, BRIP1, MRE11 | >10% |
Fusion gene | NTRK, NRG1, ALK, RAF, RET, MET, FGFR2/3, ROS | 5% |
Genome stability | MSI-H, TMB, MMR-D (MLH1, MLH3, MSH2, MSH3, MSH6, PMS1, PMS2, POLE, EPCAM) | 1% |
Others | BRAF, HER2 | 1% |
[1] |
HAYASHI A, HONG J, IACOBUZIO-DONAHUE C A. The pancreatic cancer genome revisited[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(7): 469-481.
doi: 10.1038/s41575-021-00463-z pmid: 34089011 |
[2] |
朱鑫哲, 李浩, 徐华祥, 等. 2021年胰腺癌研究及诊疗新进展[J]. 中国癌症杂志, 2022, 32(1): 1-12.
doi: 10.19401/j.cnki.1007-3639.2022.01.001 |
ZHU X Z, LI H, XU H X, et al. Advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2021[J]. China Oncol, 2022, 32(1): 1-12. | |
[3] |
QIAN Y Z, GONG Y T, FAN Z Y, et al. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma[J]. J Hematol Oncol, 2020, 13(1): 130.
doi: 10.1186/s13045-020-00958-3 |
[4] | 雷洋洋, 王小林. “精准医学”模式下胰腺癌防治的探索与进展[J]. 复旦学报(医学版), 2021, 48(2): 255-260. |
LEI Y Y, WANG X L. Exploration and progress in prevention and treatment of pancreatic cancer under the “precision medicine” model[J]. Fudan Univ J Med Sci, 2021, 48(2): 255-260. | |
[5] |
GOLAN T, HAMMEL P, RENI M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer[J]. N Engl J Med, 2019, 381(4): 317-327.
doi: 10.1056/NEJMoa1903387 |
[6] |
PISHVAIAN M J, BLAIS E M, BRODY J R, et al. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial[J]. Lancet Oncol, 2020, 21(4): 508-518.
doi: S1470-2045(20)30074-7 pmid: 32135080 |
[7] |
PISHVAIAN M J, BENDER R J, HALVERSON D, et al. Molecular profiling of patients with pancreatic cancer: initial results from the Know Your Tumor initiative[J]. Clin Cancer Res, 2018, 24 (20): 5018-5027.
doi: 10.1158/1078-0432.CCR-18-0531 pmid: 29954777 |
[8] |
KLEEFF J, MICHALSKI C W. Precision oncology for pancreatic cancer in real-world settings[J]. Lancet Oncol, 2020, 21(4): 469-471.
doi: S1470-2045(20)30148-0 pmid: 32135081 |
[9] |
AUNG K L, FISCHER S E, DENROCHE R E, et al. Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial[J]. Clin Cancer Res, 2018, 24(6): 1344-1354.
doi: 10.1158/1078-0432.CCR-17-2994 pmid: 29288237 |
[10] |
CHANTRILL L A, NAGRIAL A M, WATSON C, et al. Precision medicine for advanced pancreas cancer: the individualized molecular pancreatic cancer therapy (IMPaCT) trial[J]. Clin Cancer Res, 2015, 21 (9): 2029-2037.
doi: 10.1158/1078-0432.CCR-15-0426 pmid: 25896973 |
[11] |
LOWERY M A, JORDAN E J, BASTURK O, et al. Real-time genomic profiling of pancreatic ductal adenocarcinoma: potential actionability and correlation with clinical phenotype[J]. Clin Cancer Res, 2017, 23 (20): 6094-6100.
doi: 10.1158/1078-0432.CCR-17-0899 pmid: 28754816 |
[12] |
DING D, JAVED A A, CUNNINGHAM D, et al. Challenges of the current precision medicine approach for pancreatic cancer: a single institution experience between 2013 and 2017[J]. Cancer Lett, 2021, 497: 221-228.
doi: 10.1016/j.canlet.2020.10.039 pmid: 33127389 |
[13] | NCCN Guidelines Version 1. 2022.Pancreatic Adenocarcinoma. |
[14] |
SCHULTHEIS B, REUTER D, EBERT M P, et al. Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase Ⅱb study[J]. Ann Oncol, 2017, 28(10): 2429-2435.
doi: 10.1093/annonc/mdx343 |
[15] | QIN S K, BAI Y X, WANG Z S, et al. Nimotuzumab combined with gemcitabine versus gemcitabine in KRAS wild-type locally advanced or metastatic pancreatic cancer: a prospective, randomized-controlled, double-blinded, multicenter, and phase Ⅲ clinical trial[C]. 2022 ASCO Annual Meeting. Abstract LBA4011. |
[16] | FUSCO M J, SAEED-VAFA D, CARBALLIDO E M, et al. Identification of targetable gene fusions and structural rearrangements to foster precision medicine in KRAS wild-type pancreatic cancer[J]. JCO Precis Oncol, 2021, 5: PO.20.00265. |
[17] |
CANON J, REX K, SAIKI A Y, et al. The clinical KRAS (G12C) inhibitor AMG 510 drives anti-tumour immunity[J]. Nature, 2019, 575(7781): 217-223.
doi: 10.1038/s41586-019-1694-1 |
[18] |
SKOULIDIS F, LI B T, DY G K, et al. Sotorasib for lung cancers with KRAS p.G12C mutation[J]. N Engl J Med, 2021, 384(25): 2371-2381.
doi: 10.1056/NEJMoa2103695 |
[19] |
LEIDNER R, SANJUAN SILVA N, HUANG H Y, et al. Neoantigen T-cell receptor gene therapy in pancreatic cancer[J]. N Engl J Med, 2022, 386(22): 2112-2119.
doi: 10.1056/NEJMoa2119662 |
[20] |
MELIEF C J M. T-cell immunotherapy against mutant KRAS for pancreatic cancer[J]. N Engl J Med, 2022, 386(22): 2143-2144.
doi: 10.1056/NEJMe2204283 |
[21] |
CAO L W, HUANG C, CUI ZHOU D, et al. Proteogenomic characterization of pancreatic ductal adenocarcinoma[J]. Cell, 2021, 184(19): 5031-5052.e26.
doi: 10.1016/j.cell.2021.08.023 pmid: 34534465 |
[22] |
ESER S, REIFF N, MESSER M, et al. Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer[J]. Cancer Cell, 2013, 23(3): 406-420.
doi: 10.1016/j.ccr.2013.01.023 |
[23] |
KO A H, BEKAII-SAAB T, VAN ZIFFLE J, et al. A multicenter, open-label phase Ⅱ clinical trial of combined MEK plus EGFR inhibition for chemotherapy-refractory advanced pancreatic adenocarcinoma[J]. Clin Cancer Res, 2016, 22 (1): 61-68.
doi: 10.1158/1078-0432.CCR-15-0979 |
[24] |
GOLAN T, KHVALEVSKY E Z, HUBERT A, et al. RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients[J]. Oncotarget, 2015, 6(27): 24560-24570.
doi: 10.18632/oncotarget.4183 |
[25] |
BAILEY P, CHANG D K, NONES K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer[J]. Nature, 2016, 531(7592): 47-52.
doi: 10.1038/nature16965 |
[26] |
GOLAN T, O'KANE G M, DENROCHE R E, et al. Genomic features and classification of homologous recombination deficient pancreatic ductal adenocarcinoma[J]. Gastroenterology, 2021, 160(6): 2119-2132.e9.
doi: 10.1053/j.gastro.2021.01.220 |
[27] | 楼文晖. 胰腺癌精准治疗现状、挑战和未来[J]. 中国实用外科杂志, 2021, 41(9): 1014-1016. |
LOU W H. The current status, challenge, and future of precision treatment for pancreatic cancer[J]. Chin J Pract Surg, 2021, 41(9): 1014-1016. | |
[28] | LAI Z W, GOLAN T, KINDLER H L, et al. POLO: Homologous recombination repair gene mutations (HRRm) in metastatic pancreatic cancer (mPaC) tumors[J]. Cancer Res, 2020, 80(<W>16 suppl): Abstract nr CT217. |
[29] |
USON P L S Jr, SAMADDER N J, RIEGERT-JOHNSON D, et al. Clinical impact of pathogenic germline variants in pancreatic cancer: results from a multicenter, prospective, universal genetic testing study[J]. Clin Transl Gastroenterol, 2021, 12(10): e00414.
doi: 10.14309/ctg.0000000000000414 |
[30] |
PISHVAIAN M J, BLAIS E M, BRODY J R, et al. Outcomes in patients with pancreatic adenocarcinoma with genetic mutations in DNA damage response pathways: results from the Know Your Tumor program[J]. JCO Precis Oncol, 2019, 3: 1-10.
doi: 10.1200/PO.19.00115 pmid: 35100730 |
[31] |
HEINING C, HORAK P, UHRIG S, et al. NRG1 fusions in KRAS wild-type pancreatic cancer[J]. Cancer Discov, 2018, 8(9): 1087-1095.
doi: 10.1158/2159-8290.CD-18-0036 |
[32] |
LAETSCH T W, DUBOIS S G, MASCARENHAS L, et al. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study[J]. Lancet Oncol, 2018, 19(5): 705-714.
doi: 10.1016/S1470-2045(18)30119-0 |
[33] |
LAWLOR R T, MATTIOLO P, MAFFICINI A, et al. Tumor mutational burden as a potential biomarker for immunotherapy in pancreatic cancer: systematic review and still-open questions[J]. Cancers (Basel), 2021, 13(13): 3119.
doi: 10.3390/cancers13133119 |
[34] |
LE D T, URAM J N, WANG H, et al. PD-1 blockade in tumors with mismatch-repair deficiency[J]. N Engl J Med, 2015, 372(26): 2509-2520.
doi: 10.1056/NEJMoa1500596 |
[35] |
HU Z I, SHIA J R, STADLER Z K, et al. Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations[J]. Clin Cancer Res, 2018, 24(6): 1326-1336.
doi: 10.1158/1078-0432.CCR-17-3099 pmid: 29367431 |
[36] |
KURZ E, HIRSCH C A, DALTON T, et al. Exercise-induced engagement of the IL-15/IL-15Rα axis promotes anti-tumor immunity in pancreatic cancer[J]. Cancer Cell, 2022, 40(7): 720-737.e5.
doi: 10.1016/j.ccell.2022.05.006 pmid: 35660135 |
[37] |
ZHU X F, CAO Y S, LIU W Y, et al. Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial[J]. Lancet Oncol, 2022, 23(3): e105-e115.
doi: 10.1016/S1470-2045(22)00066-3 pmid: 35240087 |
[38] | HENDIFAR A, BLAIS E M, WOLPIN B, et al. Retrospective case series analysis of RAF family alterations in pancreatic cancer: real-world outcomes from targeted and standard therapies[J]. JCO Precis Oncol, 2021, 5: PO.20.00494. |
[39] |
AGUIRRE A J, NOWAK J A, CAMARDA N D, et al. Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine[J]. Cancer Discov, 2018, 8(9): 1096-1111.
doi: 10.1158/2159-8290.CD-18-0275 pmid: 29903880 |
[40] |
CHOU A, WADDELL N, COWLEY M J, et al. Clinical and molecular characterization of HER2 amplified-pancreatic cancer[J]. Genome Med, 2013, 5(8): 78.
doi: 10.1186/gm482 pmid: 24004612 |
[41] |
KLEIN A P, BRUNE K A, PETERSEN G M, et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds[J]. Cancer Res, 2004, 64(7): 2634-2638.
pmid: 15059921 |
[42] |
BRUNE K A, LAU B, PALMISANO E, et al. Importance of age of onset in pancreatic cancer kindreds[J]. J Natl Cancer Inst, 2010, 102(2): 119-126.
doi: 10.1093/jnci/djp466 pmid: 20068195 |
[43] | HU C L, LADUCA H, SHIMELIS H, et al. Multigene hereditary cancer panels reveal high-risk pancreatic cancer susceptibility genes[J]. JCO Precis Oncol, 2018, 2. PO. 17. 00291. |
[44] |
VARGHESE A M, SINGH I, SINGH R, et al. Early-onset pancreas cancer: clinical descriptors, genomics, and outcomes[J]. J Natl Cancer Inst, 2021, 113(9): 1194-1202.
doi: 10.1093/jnci/djab038 pmid: 33755158 |
[45] |
CHMIELECKI J, HUTCHINSON K E, FRAMPTON G M, et al. Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes[J]. Cancer Discov, 2014, 4(12): 1398-1405.
doi: 10.1158/2159-8290.CD-14-0617 |
[46] |
JIAO Y C, YONESCU R, OFFERHAUS G J, et al. Whole-exome sequencing of pancreatic neoplasms with acinar differentiation[J]. J Pathol, 2014, 232(4): 428-435.
doi: 10.1002/path.4310 |
[47] | 王欢, 金钢. 胰腺癌精准治疗的现状和展望[J]. 中国普通外科杂志, 2021, 30(9): 997-1005. |
WANG H, JIN G. Current status and future perspective of precision medicine in pancreatic cancer treatment[J]. Chin J Gen Surg, 2021, 30(9): 997-1005. | |
[48] |
COLLISSON E A. Bringing pancreas cancer into the lab[J]. Cancer Discov, 2018, 8(9): 1062-1063.
doi: 10.1158/2159-8290.CD-18-0811 pmid: 30181169 |
[49] |
BRAR G, BLAIS E M, JOSEPH BENDER R, et al. Multi-omic molecular comparison of primary versus metastatic pancreatic tumours[J]. Br J Cancer, 2019, 121(3): 264-270.
doi: 10.1038/s41416-019-0507-5 |
[1] | XIAO Yuling, ZHU Xiuzhi, JIANG Yizhou, SHAO Zhimin. New research advances and future prospect in precision treatment of triple-negative breast cancer [J]. China Oncology, 2022, 32(8): 669-679. |
[2] | ZHOU Wenbin, XIE Hui, DING Qiang, WANG Shui. New research progress of microwave ablation in the local precise treatment of early-stage breast cancer: the prospect of combined immunotherapy is promising [J]. China Oncology, 2022, 32(8): 698-704. |
[3] | SU Chunxia, ZHOU Caicun. Current status and future directions of immunotherapy for advanced non-small cell lung cancer [J]. China Oncology, 2022, 32(6): 478-486. |
[4] | YU Silai, NI Jianjiao, ZHU Zhengfei. Treatment of unresectable locally advanced non-small cell lung cancer in the era of immunotherapy: status and prospects [J]. China Oncology, 2022, 32(6): 487-498. |
[5] | LI Xiaoqiu, CD30 Positive Lymphoma Pathology Expert Group. Detection of CD30 expression in lymphomas: status and challenges [J]. China Oncology, 2022, 32(6): 512-518. |
[6] | SU Jiaqi, XU Wenhao, TIAN Xi, ANWAIE Aihetaimujiang, QU Yuanyuan, SHI Guohai, ZHANG Hailiang, YE Dingwei. New strategies for combined with immunotherapy of clear cell renal cell carcinoma: advances in aerobic glycolysis [J]. China Oncology, 2022, 32(4): 287-297. |
[7] | CHEN Guangliang, WU Fangtian, CAO Junning. Advances in research on EBV positive diffuse large B-cell lymphoma, not otherwise specified [J]. China Oncology, 2022, 32(3): 258-267. |
[8] | LI Yujie, CHEN Hao. Potential of targeting TROP2 in the treatment of pancreatic cancer [J]. China Oncology, 2022, 32(3): 268-273. |
[9] | WU Mengyin, WU Chunxiao, PANG Yi, WANG Chunfang, GU Kai, GONG Yangming, BAO Pingping, SHI Liang, DOU Jianming, XIANG Yongmei, SHI Yan. Incidence and mortality of pancreatic cancer in Shanghai 2016 and epidemic trend analysis from 2002 to 2016 [J]. China Oncology, 2022, 32(2): 97-105. |
[10] | ZHU Xinzhe, LI Hao, XU Huaxiang, LUO Guopei, YU Xianjun. Advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2021 [J]. China Oncology, 2022, 32(1): 1-12. |
[11] | YANG Shipeng , LIU Ying , WANG Xinyue , YANG Yang , QUAN Jishu , LIN Zhenhua . Clinical significance of PKLR overexpression in the pancreatic cancer [J]. China Oncology, 2021, 31(8): 704-713. |
[12] | XIE Mengqing, CHU Xiangling, ZHOU Juan, SU Chunxia. The advances in immunotherapy biomarkers of small cell lung cancer [J]. China Oncology, 2021, 31(7): 635-639. |
[13] | ZHU Jun, WU Xiaohua. Leading research progress and prospect of gynecological oncology in 2020 [J]. China Oncology, 2021, 31(4): 250-256. |
[14] | GUO Ye , ZHANG Chenping . Expert consensus on the treatment of recurrent/metastatic squamous cell carcinoma of the head and neck with anti-EGFR monoclonal antibody (2021 edition) [J]. China Oncology, 2021, 31(12): 1220-1232. |
[15] | TANG Rong, SHI Si, ZHANG Bo, XU Jin, WANG Wei, YU Xianjun. Advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2020 [J]. China Oncology, 2021, 31(1): 1-10. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||
沪ICP备12009617
Powered by Beijing Magtech Co. Ltd